Overview
TNYA market data
Price History
TNYA price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.59 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.85 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.53 – $2.35 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $162.7 · P/B 1.25.
Company News
8-K filing — Tenaya Therapeutics, Inc. (TNYA)SEC EDGAR · Jul 2, 2026, 9:00 PM
Tenaya Therapeutics Appoints Eric Hyllengren CFO, Effective July 13Benzinga · Jun 29, 2026, 12:40 PM
Tenaya Therapeutics To Report New Interim Data From Cohort 1 And 2 Of Ongoing MyPEAK-1 Phase 1b/2 Trial Of TN-201 Gene Therapy For Adults With MYBPC3-Associated Hypertrophic Cardiomyopathy On June 3Benzinga · Jun 2, 2026, 8:32 PM
Tenaya Therapeutics' Gene Therapy Data Highlights Early Heart Rhythm ImprovementsBenzinga · May 15, 2026, 2:15 PM